Q32 Bio, a biotechnology company developing treatments for patients with severe autoimmune and inflammatory diseases, secured $46 million in Series A funding, led by Atlas Venture, to officially launch, the company announced Thursday.
Subscribe to the Crunchbase Daily
The Cambridge, Massachusetts, company was also seeded and incubated by Atlas Venture. Q32 Bio’s lead candidate, ADX-914, was developed to re-regulate and restore healthy immune regulation in numerous autoimmune and inflammatory diseases, the company said in a written statement.
“Autoimmune and inflammatory diseases are driven by dysregulation of the immune response,” Q32 Bio CEO Michael Broxson said in the statement.
Autoimmune diseases–lupus and multiple sclerosis for example–cause the immune system to begin attacking the body. A Phase 1 human clinical trial for ADX-914 is planned for late 2020, the company said.
In addition to Atlas Venture, the new funding round included OrbiMed Advisors, Abingworth, Sanofi Ventures, University of Colorado and Children’s Hospital Colorado Center for Innovation.
Q32 Bio is also working on a platform to provide tissue-targeted regulation, ADX-097, which will go into clinical trials in late 2021, the company said. Because some autoimmune and inflammatory diseases become hyperactivated, causing the immune system to attack and damage healthy tissue, Q32 Bio’s approach aims to block those pathogens responsible.
“This gives us a running start in developing therapies that may improve and save lives,” Broxson said.
Illustration: Li-Anne Dias